6,7,8,9-四氢-5H-苯并环庚烯-7-羧酸 | 1400229-72-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6,7,8,9-四氢-5H-苯并环庚烯-7-羧酸
• 英文名称: 6,7,8,9-tetrahydro-5H-benzo[7]annulene-7-carboxylic acid
• CAS: 1400229-72-2
• 化学式: C₁₂H₁₄O₂
• 分子量: 190.242
• InChiKey: FGVCREOLYLRJCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6,7,8,9-四氢-5H-苯并环庚烯-7-羧酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 、 三氯乙腈 作用下， 以 1,4-二氧六环 、 水 、 乙腈 为溶剂， 反应 0.75h， 生成 8-(1-methyl-1H-pyrazol-4-yl)-6-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-ylcarbonyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepine trifluoroacetate
  参考文献：
  名称：

  [EN] NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES
  [FR] NOUVEAUX COMPOSÉS TRICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'ENZYMES IDH MUTANTES

  摘要：

  本发明涉及式(I)的三环化合物，其为一种或多种突变IDH酶的抑制剂；其中A为-C(R1)=或-N=；X从以下组中选择：(II-i)和(II-ii)。本发明还涉及所述三环化合物在潜在治疗或预防涉及一种或多种突变IDH酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。

  公开号：

  WO2016089830A1
• 作为产物：
  描述：

  7-(Nitromethyl)-6,7,8,9-tetrahydro-5H-benzo[alpha][7]annulene 、 potassium tert-butylate 、 potassium permanganate 、 sodium hydrogensulfite 、 四氢呋喃 在 sodium hydroxide 、 水 、 甲基叔丁基醚 、 magnesium sulfate 作用下， 以 水 、 甲基叔丁基醚 为溶剂， 反应 2.42h， 以to give the title compound (73 g, 89%)的产率得到6,7,8,9-四氢-5H-苯并环庚烯-7-羧酸
  参考文献：
  名称：

  Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain

  摘要：

  本发明提供了式（I）的化合物；其药学上可接受的盐和N-氧化物，其中A，B，D和E是C或N，但其中一个或多个是N，R1，R2，R3，R4，R5和R6是简单的取代基，n是0-3，y是芳基，杂环芳基，碳环芳基或融合的碳环芳基基团；作为VR-1拮抗剂，用于治疗疼痛和/或炎症占优势的疾病或症状；同样的用于制造药物、包含它们的制剂和利用它们的治疗方法。

  公开号：

  US20050107388A1

文献信息

• [EN] NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES<br/>[FR] NOUVEAUX COMPOSÉS TRICYCLIQUES COMME INHIBITEURS D'ENZYMES IDH MUTANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089833A1

  公开（公告）日：2016-06-09

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is -C(R1)= or -N=; and X is selected from the group consisting of: (II-i), (II-ii), (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，这些化合物是一种或多种突变IDH酶的抑制剂：(I)；其中A为-C(R1)=或-N=；X选自以下组中的一种：(II-i)、(II-ii)、(II-iii)和(II-iv)。本发明还涉及所述三环化合物在潜在治疗或预防涉及一种或多种突变IDH酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。
• Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain
  申请人：——

  公开号：US07285563B2

  公开（公告）日：2007-10-23

  The present invention provides compounds of formula (I); pharmaceutically acceptable salts and N-oxides thereof in which A, B, D and E are C or N with the proviso that one or more are N, R1, R2, R3, R4, R5 and R6 are simple substituents, n is 0-3 and y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; as VR-1 antagonists for treating conditions or diseases in which pain and/or inflammation predominates; the use of the same for manufacturing medicaments, pharmaceutical compositions comprising them and methods of treatment utilizing them

  本发明提供了式(I)的化合物；其药学上可接受的盐和N-氧化物，其中A、B、D和E是C或N，但至少一个是N，R1、R2、R3、R4、R5和R6是简单的取代基，n为0-3，y是芳香基，杂环芳基，碳环基或融合碳环基；作为VR-1拮抗剂，用于治疗疼痛和/或炎症占优势的疾病或症状；将其用于制造药物，制备包含它们的制药组合物和利用它们的治疗方法。
• Tricyclic compounds as inhibitors of mutant IDH enzymes
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10086000B2

  公开（公告）日：2018-10-02

  The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I); wherein A is —C(R1)= or —N═; and X is selected from the group consisting of: (II-i), (II-ii), (I) (II-iii), and (II-iv). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

  本发明涉及式(I)的三环化合物，它是一种或多种突变IDH酶的抑制剂：(I)；其中A是-C(R1)＝或-N═；X选自由(II-i)、(II-ii)、(I)(II-iii)和(II-iv)组成的组。本发明还涉及本文所述三环化合物在潜在治疗或预防涉及一种或多种突变 IDH 酶的癌症中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗此类癌症中的用途。
• NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3226690B1

  公开（公告）日：2020-05-20
• NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES
  申请人：ENYO Pharma

  公开号：EP3749650A1

  公开（公告）日：2020-12-16